About
About Bukwang Pharmaceutical Co., Ltd
Bukwang Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells prescription and over-the-counter drugs. The company offers ethical drugs, such as Dexid and Thioctacid, Legalon, Synthyroid, Feroba-You SR, Latuda, Zaledeep, Ariplus, and Circaledeep to treat diabetic peripheral neuropathy, hepatitis, hypothyroidism, iron-deficiency anemia, insomnia, alzheimer's, as well as antipsychotic medication. It also provides Tacenol, a fever and pain relief medication; Alaxyl, a laxative; Tavex Gel, a topical gel; Hexamedine, a mouthwash; Coritussal, a cold medication; Phazyme Complex, a gastrointestinal medication; Mega-Vai, a high-potency multivitamin supplement; MG Max Plus B, a high-potency magnesium supplement; Chokchokeorin Collagen Biotin, a collagen supplement; Insa Med F, an oral health supplement; Entax, an oral health supplement; and Eskimo rTG Omega-3 Prime, an Omega-3 supplement. In addition, the company offers SirinMED F and Antiplaque Ssen Strong, a toothpaste. Further, it is involved in developing CP-012, a therapeutic candidate for morning akinesia in Parkinson's disease which is in Phase 2 initiation; CP-102, which is in preclinical trial to treat Canavan disease; Others, which is in preclinical trial to treat rare diseases; and AhR Antagonist, an immune-metabolic which in preclinical trial for the treatment of AhR-mediated disorders. Additionally, the company develops small-molecule antagonists targeting the aryl hydrocarbon receptor (AhR) pathway. Bukwang Pharmaceutical Co., Ltd. was founded in 1960 and is headquartered in Seoul, South Korea.
Research context
Bukwang Pharmaceutical Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
Apr 1, 2021
Bukwang Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 13.5% below its 200 day moving average.
From a valuation standpoint, the stock is 0.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.5.
Bukwang Pharmaceutical Co., Ltd's total revenue sank by 3.7% to $49B since the same quarter in the previous year.
Its net income has dropped by 126.9% to $-2B since the same quarter in the previous year.
Finally, its free cash flow grew by 104.7% to $404M since the same quarter in the previous year.
Based on the above factors, Bukwang Pharmaceutical Co., Ltd gets an overall score of 2/5.